• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call

St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call

May 15, 2012 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.

The Enlightn system is one of the 1st to use multiple electrodes to ablate the nerves that contribute to high blood pressure, possibly improving consistency and procedural reliability, according to a press release.

The Enlightn system will compete against some big players, including Medtronic’s (NYSE:MDT) Symplicity system, gained through the January 2011 acquisition of Ardian, which is on the road to FDA review with clinical trials approved in the U.S. last summer. The device has CE Mark approval and TGA listing in Australia and last month won clearance from Health Canada.

Fellow med-tech giant Covidien (NYSE:COV) recently vaulted into the renal denervation space with a surprise introduction of its OneShot system, which also has CE Mark approval in the European Union. The OneShot system was gained through the acquisition of Maya Medical late last month in a deal worth up to $230 million.

The renal denervation space is a hot one, and not without reason. Cleveland Clinic named catheter-based renal denervation to control resistant hypertension the No. 1 innovation for 2012, with the potential to spread to treating chronic kidney disease, insulin resistance and heart failure.

St. Jude also released data from its Fame II trial, demonstrating the value of fractional flow reserve-guided assessment in determining which patients are best treated with optimal medical therapy rather than percutaneous coronary intervention, potentially lowering the need for unplanned hospital readmission and urgent revascularization in patients with stable coronary artery disease.  Read more

 Biotronik unveils positive outcomes from the 12-month follow-up of patients implanted with the Pro-Kinetic Energy bare metal stent system in more than 1,000 patients in patients with acute coronary syndrome or small vessels, as well as in patients with diabetes and the elderly. Read more

 Volcano (NSDQ:VOLC) plans to highlight its FFR and Instant Wave-Free Ration Functionality product portfolio, showcasing new measurement technologies, including the company’s latest Primewire Prestige Plus pressure guidewire. Read more

 Abbott (NYSE:ABT) wins expanded CE Mark indication for its Xience Prime and Xience V everolimus-eluting coronary stents, now approved for a minimum of 3 months of dual anti-platelet therapy, the shortest duration for any drug-eluting stent in Europe. Read more

 Svelte Medical closes patient enrollment in its Direct drug-eluting stent study, a 1st-in-man study designed to evaluate its All-In-One stent system. Read more

 Stentys launches its Stentys AC aspiration catheter, designed to safely remove clot chunks from the coronary arteries prior to implanting a stent. Read more

 Neovasc (NYSE:NVC) touts clinical studies for its Tiara transcatheter mitral valve disease therapies, showing successful implantation in animal models. Read more

 Infraredx introduces its TVC device, an intravascular imaging system for assessing vessel composition and structure by using integrated near-infrared spectroscopy, enhanced intravascular ultrasound and imaging technology. Read more

 Capella Medical Devices releases 6 month follow-up data for its Sideguard coronary sidebranch system, designed to treat bifurcation disease.  Read more

Filed Under: News Well Tagged With: Abbott, Boston Scientific, Capella Inc., Clinical Trials, InfraReDx Inc., neovasc, On Call, Renal, Stentys, stjudemedical, Svelte Medical Systems Inc., Volcano Corp.

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy